New obesity drug HM17321 enters early human safety trials
NCT ID NCT07219589
First seen Oct 31, 2025 · Last updated May 06, 2026 · Updated 28 times
Summary
This early-stage study is testing a new drug called HM17321 in healthy and obese adults to see if it is safe and how the body processes it. About 90 participants will receive either the drug or a placebo. The goal is to check for side effects and measure drug levels in the blood, not yet to prove weight loss.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Medpace Clinical Pharmacology Unit
RECRUITINGCincinnati, Ohio, 45227, United States
Contact
Conditions
Explore the condition pages connected to this study.